Compounds > ilexgenin a
Page last updated: 2024-11-13

ilexgenin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ilexgenin A: extract from the leaves of the plant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21672638
MeSH IDM0443134

Synonyms (9)

Synonym
108524-94-3
ilexgenin a
(3s,4r,4ar,6ar,6bs,8as,11r,12r,12as,14ar,14br)-3,12-dihydroxy-4,6a,6b,11,12,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,11,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid
MS-29339
E88590
DTXSID301319106
CS-0032790
HY-N6255
AKOS040750438

Research Excerpts

Overview

Ilexgenin A (IA) is a novel pentacyclic triterpenoid. extracted from leaves of Ilex hainanensis Merr. It has beneficial effects on metabolic homeostasis.

ExcerptReferenceRelevance
"Ilexgenin A is a triterpenoid from ShanLv Cha with beneficial effects on metabolic homeostasis. "( Ilexgenin A restrains CRTC2 in the cytoplasm to prevent SREBP1 maturation via AMP kinase activation in the liver.
Li, P; Liu, B; Lu, Y; Ma, J; Wen, X; Yang, J, 2022)		3.61
"Ilexgenin A is a natural triterpenoid with beneficial effects on lipid disorders. "( Ilexgenin A inhibits endoplasmic reticulum stress and ameliorates endothelial dysfunction via suppression of TXNIP/NLRP3 inflammasome activation in an AMPK dependent manner.
Chen, MH; Chen, XQ; Li, Y; Liu, BL; Qin, MJ; Wang, Q; Wen, XD; Yang, J; Zhang, T, 2015)		3.3
"Ilexgenin A (IA) is a novel pentacyclic triterpenoid, which extracted from leaves of Ilex hainanensis Merr. "( Ilexgenin A, a novel pentacyclic triterpenoid extracted from Aquifoliaceae shows reduction of LPS-induced peritonitis in mice.
Liu, C; Qiu, X; Rong, Y; Sun, W; Sun, Y; Zhang, L; Zhang, Y; Zhao, H, 2017)		3.34

Treatment

ExcerptReferenceRelevance
"The Ilexgenin A treatment groups showed no apparent side effects during the treatment period."( Ilexgenin A induces B16-F10 melanoma cell G1/S arrest in vitro and reduces tumor growth in vivo.
Chen, J; Ge, LT; Gu, RX; Jia, XQ; Liu, C; Sun, WD; Sun, Y; Yang, H; Zhang, YQ, 2015)		2.34

Pharmacokinetics

ExcerptReferenceRelevance
" The method was validated in terms of selectivity, linearity and sensitivity, and shows advantages in monitoring the pharmacokinetic behaviors of these three compounds."( Pharmacokinetic study of major bioactive components in rats after oral administration of extract of Ilex hainanensis by high-performance liquid chromatography/electrospray ionization mass spectrometry.
Chen, LH; Chen, XQ; Cui, WX; Lv, F; Wang, Q; Wen, XD; Yang, J, 2013)		0.39
" Although many studies about the total saponins have been reported, the absorption triterpenoids and pharmacokinetic behaviors were unclear."( Rapid profiling and pharmacokinetic studies of multiple potential bioactive triterpenoids in rat plasma using UPLC/Q-TOF-MS/MS after oral administration of Ilicis Rotundae Cortex extract.
Jin, J; Li, H; Liu, Z; Ruan, Q; Tong, Y; Xuan, S; Yang, B; Zhao, Z, 2018)		0.48
" No significant changes were observed in pharmacokinetic parameters of SV and simvastatin hydroxy acid in the IA plus SV co-treated group in comparison with those in the group treated with SV alone."( Ilexgenin A enhances the effects of simvastatin on non-alcoholic fatty liver disease without changes in simvastatin pharmacokinetics.
Li, P; Lu, YW; Wen, XD; Yang, J; Zhang, L; Zhu, YC, 2018)		1.92
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (6.67)18.2507
2000's0 (0.00)29.6817
2010's12 (80.00)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.80 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycerol
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.		2.1510alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		2.1510pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
pyruvic acid
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.		2.15102-oxo monocarboxylic acidcofactor;
fundamental metabolite
azoxymethane
Azoxymethane: A potent carcinogen and neurotoxic compound. It is particularly effective in inducing colon carcinomas.		2.2110
simvastatin
Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.		7.1710delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
sorafenib
[no description available]		7.1510(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.0810cyclodextrin
glycosides
[no description available]		2.0810
chlorogenic acid
caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.		2.0810cinnamate ester;
tannin		food component;
plant metabolite
beta-escin
[no description available]		2.7830
rutundic acid
rutundic acid: isolated from the leaves of Hex pupurea; structure in first source		2.1710triterpenoidmetabolite
pedunculoside
pedunculoside: from leaves of Ilex chinensis; structure given in first source		2.1710
ilexsaponin a1
ilexsaponin A1: extract from the leaves of the plant		210
ConditionIndicatedRelationship StrengthStudiesTrials
Insulin Sensitivity
[description not available]		02.1510
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		07.1510
Fatty Liver, Nonalcoholic
[description not available]		02.5220
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.830
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		07.5220
Atherogenesis
[description not available]		02.5720
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		07.5720
Colorectal Cancer
[description not available]		02.2110
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.2110
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.2110
Hyperlipemia
[description not available]		02.0810
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		02.0810
B16 Melanoma
[description not available]		02.1110
Cancer of Skin
[description not available]		02.1110
Skin Neoplasms
Tumors or cancer of the SKIN.		02.1110
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		02.1110
Hepatocellular Carcinoma
[description not available]		02.1510
Cancer of Liver
[description not available]		02.1510
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.1510
Liver Neoplasms
Tumors or cancer of the LIVER.		02.1510
Primary Peritonitis
[description not available]		02.1510
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		07.1510
Liver Steatosis
[description not available]		02.0810
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		02.0810